Salix Pharmaceuticals Income Statement
View: Annual | Quarterly
This data is provided as per license from EDGAR Online
| Dec 07 | Dec 06 | Dec 05 | |
|---|---|---|---|
| Revenue | 235.8 | 208.5 | 154.9 |
| Cost of Goods Sold | 55.0 | 41.4 | 34.3 |
| Gross Profit | 180.8 | 167.1 | 120.6 |
| Gross Profit Margin | 76.7% | 80.1% | 77.8% |
| SG&A Expense | 158.3 | 130.3 | 178.2 |
| Depreciation & Amortization | 10.6 | 6.5 | 3.4 |
| Operating Income | 11.9 | 30.3 | (61.1) |
| Operating Margin | 5.0% | 14.5% | -- |
| Nonoperating Income | 3.3 | 2.5 | 1.2 |
| Nonoperating Expenses | -- | -- | -- |
| Income Before Taxes | 15.2 | 32.9 | (59.8) |
| Income Taxes | 6.9 | 1.4 | 0.7 |
| Net Income After Taxes | 8.2 | 31.5 | (60.6) |
| Continuing Operations | 8.2 | 31.5 | (60.6) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 8.2 | 31.5 | (60.6) |
| Total Net Income | 8.2 | 31.5 | (60.6) |
| Net Profit Margin | 3.5% | 15.1% | -- |
| Diluted EPS from Total Net Income ($) | 0.17 | 0.65 | (1.55) |
| Dividends per Share | -- | -- | -- |
This data is provided as per license from EDGAR Online
